Enhancement of anticancer activity by silibinin and paclitaxel combination on the ovarian cancer

Pashaei-Asl, Fatima; Pashaei-Asl, Roghiyeh; Khodadadi, Khodadad; Akbarzadeh, Abolfazl; Ebrahimie, Esmaeil; Pashaiasl, Maryam

doi:10.1080/21691401.2017.1374281

Cited by 51 publications

(34 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, silibinin is also found to display various biological activities including anti-oxidative, anti-proliferative, anti-bacterial, anti-fungal, neuro-protective, anti-leishmanial, anti-osteoclastic and anti-metastatic activities [310][311][312][313][314][315][316][317]. Previous studies have reported that silibinin exerts remarkable effects in numerous cancers such as renal, hepatocellular and pancreatic carcinoma, bladder, breast, colorectal, ovarian, lung, salivary gland, prostate and gastric cancers, through the induction of apoptosis, inhibition of tumor growth, metastasis and angiogenesis [318][319][320][321][322][323][324][325][326][327][328].…”

Section: Silibininmentioning

confidence: 99%

See 1 more Smart Citation

Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine

et al. 2019

View full text Add to dashboard Cite

Numerous natural products originated from Chinese herbal medicine exhibit anti-cancer activities, including antiproliferative, pro-apoptotic, anti-metastatic, anti-angiogenic effects, as well as regulate autophagy, reverse multidrug resistance, balance immunity, and enhance chemotherapy in vitro and in vivo. To provide new insights into the critical path ahead, we systemically reviewed the most recent advances (reported since 2011) on the key compounds with anti-cancer effects derived from Chinese herbal medicine (curcumin, epigallocatechin gallate, berberine, artemisinin, ginsenoside Rg3, ursolic acid, silibinin, emodin, triptolide, cucurbitacin B, tanshinone I, oridonin, shikonin, gambogic acid, artesunate, wogonin, β-elemene, and cepharanthine) in scientific databases (PubMed, Web of Science, Medline, Scopus, and Clinical Trials). With a broader perspective, we focused on their recently discovered and/or investigated pharmacological effects, novel mechanism of action, relevant clinical studies, and their innovative applications in combined therapy and immunomodulation. In addition, the present review has extended to describe other promising compounds including dihydroartemisinin, ginsenoside Rh2, compound K, cucurbitacins D, E, I, tanshinone IIA and cryptotanshinone in view of their potentials in cancer therapy. Up to now, the evidence about the immunomodulatory effects and clinical trials of natural anti-cancer compounds from Chinese herbal medicine is very limited, and further research is needed to monitor their immunoregulatory effects and explore their mechanisms of action as modulators of immune checkpoints.

show abstract

Section: Silibininmentioning

confidence: 99%

“…The combination of silibinin and other drugs are used in cancer treatment to enhance the efficacy of anti-cancer effects [324,[357][358][359]. The combination of curcumin and silibinin enhances the inhibition of cell growth and reduction in telomerase gene expression compared to silibinin alone in human breast cancer T47D cells [357].…”

Section: Silibininmentioning

confidence: 99%

Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine

et al. 2019

View full text Add to dashboard Cite

show abstract

“…There is (40%) overexpression of genes in this pathway that is associated with BRCA1 or BRCA2 mutations and BRCA1 methylation; 2-Mutations of TP53 (96%); 3-The Rb pathway dysfunction occurs in 67% of highgrade OCs (Network, 2011;Romero & Bast, 2012). Ovarian Carcinogenesis was created by the interference of 90% P53, up to 40% p21 (WAF-1), up to 90% cyclin D1 and up to 70% cyclin B1 (Bast, Hennessy, & Mills, 2009;Landen, Birrer, & Sood, 2008;Pashaei-Asl et al, 2018).…”

Section: Introductionmentioning

confidence: 99%

“…P53 mutation is an initial occurrence in ovarian cancer cells. This event is intensely related to high-grade ovarian neoplasms (Pashaei-Asl et al, 2018;Skomedal et al, 1997). P21 (CIP1/WAF1) or CDKN1A (cyclin-dependent kinase inhibitor 1A) gene is located on chromosome 6p21.2 in humans (Harper, Adami, Wei, Keyomarsi, & Elledge, 1993;Xiong et al, 1993).…”

Section: Introductionmentioning

confidence: 99%

The human amniotic fluid mesenchymal stem cells therapy on, SKOV3, ovarian cancer cell line

Aziz

Fardyazar

Pashaiasl

2019

Molec Gen & Gen Med

Self Cite

View full text Add to dashboard Cite

Purpose One of the most common malignancies peculiar to female health with few symptoms, low response to therapy, difficult diagnosis, frequent relapse, and high mortality, is ovarian cancer. Thus, our experiment, using Human amniotic fluid mesenchymal stem cells (hAFMSCs) as a therapeutic tool, aims to find an efficient treatment approach for patients suffering from SKOV3 ovarian cancer. Material & Methods In this study, we obtained 5 ml amniotic fluid from 16–20 week pregnant women who underwent amniocentesis for routine prenatal diagnosis by karyotyping in Al‐Zahra Hospital of Tabriz University of Medical Sciences, Iran. Using trans wells in 24 wells plate, hAFMSCs were isolated from all samples, co‐cultured with SKOV3 ovarian cancer cell line, and characterized via flow cytometry and RT‐PCR. Human skin fibroblast cells (HSFCs) were isolated and used as a negative control. SKOV3 and HSFCs' viability after 5 days was evaluated by MTT assay. Cell cycle and apoptotic genes were analyzed by real‐time PCR. Results We successfully isolated and characterized hAFMSCs through it positivity for CD44 and CD90 specific mesenchymal stem cell markers and negativity for CD31 and CD45. Oct4 and NANOG were evaluated by RT‐PCR as pluripotency markers, and visualized on 2% gel electrophoresis. We established hAFMS cell lines after 5 days of co‐culturing the SKOV3 cells, viability was decreased; however, HSFCs did not show toxicity by MTT assay. The genes indicated upregulation and high expression by a real‐time PCR. Conclusions Our findings showed that hAFMSCs have natural tumor tropism, and can release soluble factors in a cell culture, which cause an efficient anticancer effect. Thus, we can use hAFMSCs for complete anticancer therapy on SKOV3 cell line at cell culture condition and possibly in vivo in the near future.

show abstract

“…Combinations of traditional Chinese medicines have been widely used to treat various diseases, including cancer [33][34][35][36]. The main advantages of this approach are the ability to reduce the dose and toxicity of the individual compounds, and to minimize or delay the induction of drug resistance [30].…”

Section: Discussionmentioning

confidence: 99%

The combined administration of parthenolide and ginsenoside CK in long circulation liposomes with targeted tLyp-1 ligand induce mitochondria-mediated lung cancer apoptosis

Jin

Zhou

Zhang

et al. 2018

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

2018) The combined administration of parthenolide and ginsenoside CK in long circulation liposomes with targeted tLyp-1 ligand induce mitochondria-mediated lung cancer apoptosis, Artificial Cells, Nanomedicine, and Biotechnology, 46:sup3, S931-S942, ABSTRACT Background: Combinations of natural products with low toxicities using tumor-targeting carriers may improve cancer treatment. The combined parthenolide and ginsenoside compound K (CK) within tLyp-1 liposomes, with the aim of improving the efficacy of lung cancer treatment.Results: In vitro studies in A549 human pulmonary adenocarcinoma cells demonstrated that parthenolide/CK tLyp-1 liposomes increased reactive oxygen species levels and induced mitochondrial apoptosis. It enters into cells via receptor-mediated uptake and micropinocytosis, followed by endosomal/lysosomal escape. In vivo studies illustrated that it produced a greater antitumor effect than combined administration of these compounds, with minimal toxicity. Conclusion: The findings of this study indicated that combined application of natural products in nanocarriers could offer attractive therapeutic options.

show abstract

Enhancement of anticancer activity by silibinin and paclitaxel combination on the ovarian cancer

Abstract: Our results showed that combination of chemotherapy drugs of silibinin and paclitaxel can be more efficient in treatment of ovarian cancer cells.

Cited by 51 publications

References 30 publications

Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine

Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine

The human amniotic fluid mesenchymal stem cells therapy on, SKOV3, ovarian cancer cell line

The combined administration of parthenolide and ginsenoside CK in long circulation liposomes with targeted tLyp-1 ligand induce mitochondria-mediated lung cancer apoptosis

Contact Info

Product

Resources

About